Pfizer Exercises Option for Sisunatovir Rights with LianBio
US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...
Pfizer
111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China
China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s...
CDE Prioritizes Review for Jiedi Pharma’s Mitotane and Other Key Drugs
The Center for Drug Evaluation (CDE) website indicates that market filings for several key drugs,...
Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...
Pfizer China Partners with Alibaba Health for Disease Education at CIIE
The 5th China International Import Expo (CIIE) saw US-based Pfizer’s China unit announce a partnership...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit
Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to...
Ascletis Signs Pact with Pfizer China for Ritonavir Tablets
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co., Ltd has...
CSPC Receives CDE Approval for Generic Version of Pfizer’s Xeljanz
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received market...
Pfizer’s Zavicefta Approved in China for Pediatric Complex Intra-Abdominal Infections
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced that it has received market approval from...
Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...
Huahai Pharma to Manufacture Pfizer’s Paxlovid for China Market
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has entered into a manufacturing and supply...
Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment...
Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach
Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...
Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...
Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines
China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...
Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment
US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...